Press News

Press News

2012.10.30 Shinshu University Hospital Approved as a Medical Institution Providing DC Vaccine Therapy as an Advanced Medical Treatment

We are pleased to announce that Shinshu University Hospital, a contracted medical institution of tella, Inc. (Head office: Chiyoda-ku, Tokyo; President & Representative Director: Yuichiro Yazaki; hereinafter “tella”) has been approved as a medical institution providing DC (dendritic cell) vaccine therapy*1 (a cancer vaccine therapy employing dendritic cells and tumor antigen peptide) as an advanced medical treatment*2. tella signed a joint research agreement with the National University Corporation Shinshu University (hereinafter “Shinshu University”) in 2008 and has been providing Shinshu University with technologies and know-how related to the DC vaccine therapy. Shinshu University Hospital has been conducting clinical research on DC vaccine therapy on the basis of these technologies and know-how and it has now been approved as a an institution providing DC vaccine therapy as an advanced medical treatment for breast cancer, lung cancer, pancreatic cancer, stomach cancer, and colorectal cancer.

As of the end of September 2012, tella provides technologies and know-how to a total of 23 contracted medical institutions, including Shinshu University, nationwide. Into the future tella will continue to promote wider diffusion of therapies using our technologies and know-how and to strive to make a contribution to an even larger number of cancer patients by supporting applications for advanced medical treatment at contracted medical institutions and other organizations. This matter will have only a negligible effect on results of operations in fiscal 2012.

Reference: Ministry of Health, Labour and Welfare website
URL: http://www.mhlw.go.jp/topics/bukyoku/isei/sensiniryo/kikan.html
(available only in Japanese language)

Reference: Shinshu University Hospital website
URL: http://wwwhp.md.shinshu-u.ac.jp/english/

TopPage